微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 64.81% | 8.3% | 3.02% | 37/159 | 50.16% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 62.91% | 0.72% | -3.05% | 41/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 64.9% | 10.6% | 11.19% | 43/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 58.36% | 2.23% | -2.48% | 54/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 59.85% | 0.46% | -4.19% | 51/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 62.46% | 3.96% | 6.45% | 44/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 58.68% | -2.96% | 2.78% | 54/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 57.09% | 15.79% | -4.16% | 60/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 59.57% | -6.15% | -0.86% | 53/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 60.09% | -15.7% | -0.63% | 52/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 60.47% | -15.85% | 22.64% | 48/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 49.31% | -36.24% | -22.32% | 80/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 63.47% | -19.19% | -10.96% | 44/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 71.28% | -7.88% | -0.81% | 33/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 71.86% | -7.2% | -7.08% | 33/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 77.34% | 7.35% | -1.53% | 26/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 78.54% | 8.74% | 1.5% | 25/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 77.38% | 6.34% | -0.07% | 29/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 77.43% | 6.96% | 7.49% | 28/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 72.04% | -10.48% | -0.25% | 38/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 72.23% | -12.77% | -0.74% | 33/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 72.76% | -9.34% | 0.51% | 32/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 72.39% | -8.55% | -10.05% | 26/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 80.48% | 1.19% | -2.8% | 21/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 82.8% | 2.16% | 3.16% | 14/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 80.26% | -4.22% | 1.4% | 18/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 79.16% | -8.92% | -0.47% | 17/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 79.53% | -7.05% | -1.87% | 19/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 81.05% | -5.9% | -3.28% | 11/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 83.8% | -4.11% | -3.58% | 12/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 86.91% | -0.16% | 1.57% | 6/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 85.56% | 1.61% | -0.65% | 14/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 86.13% | 6.07% | -1.45% | 8/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 87.39% | 8.65% | 0.4% | 5/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 87.04% | 13.85% | 3.36% | 5/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 84.21% | 5.02% | 3.71% | 12/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 81.2% | -0.1% | 0.96% | 6/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 80.43% | 1.14% | 5.2% | 7/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 76.46% | -0.8% | -4.65% | 9/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 80.18% | -0.88% | -1.35% | 9/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 81.28% | 1.72% | 2.21% | 6/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 79.53% | 1.55% | 3.18% | 6/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 77.07% | 2.19% | -4.73% | 6/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |